Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 13, 2023
Subject: Item 8.01 Other Events regarding banking relationships and liquidity in the context of the Silicon Valley Bank situation.
Key Financial Metrics
This filing does not report specific revenue, profit, or cash flow figures for a reporting period. It focuses on liquidity and debt capacity:
- Cash Holdings: The company holds a de minimis amount of cash in accounts with Silicon Valley Bank and its foreign affiliates.
- Debt Facilities: The company maintains a Credit Agreement with Citizens Bank, N.A., Wells Fargo Bank, and Silicon Valley Bank.
- Term Loan: $40.0 million.
- Revolving Credit Facility: $25.0 million total, including a $10.0 million sub-facility for letters of credit and a $10.0 million swingline loan sub-facility.
Material Changes and Liquidity Assessment
The filing addresses potential liquidity risks arising from the instability of Silicon Valley Bank:
- Access to Cash: Management expects full access to the de minimis cash held at Silicon Valley Bank based on U.S. Department of Treasury announcements.
- Impact Assessment: The company states that any inability to access these funds would not have a material impact on its financial condition or operations.
- Debt Capacity: Management expects that available cash, cash generated from operations, and debt capacity from lenders other than Silicon Valley Bank will be sufficient to finance current operating plans and cash flow obligations.
Guidance, Risks, and Forward-Looking Statements
The filing contains forward-looking statements regarding future liquidity and operational continuity. Key points include:
- Outlook: The company anticipates sufficient funding to meet obligations even if Silicon Valley Bank cannot fund its portion of the Credit Facility.
- Risks: Actual results may differ due to known and unknown risks, uncertainties, and other factors. Detailed risk factors are referenced in the Annual Report on Form 10-K for the year ended December 31, 2022.
- Contingencies: The primary contingency discussed is the potential inability of Silicon Valley Bank to fund its portion of the Credit Facility or provide access to cash deposits.
Investor Verification Checklist
- Verify the exact amount of cash held at Silicon Valley Bank to confirm the "de minimis" classification.
- Review the Credit Agreement (Exhibit 10.18 to the 2022 10-K) to understand specific covenants and the role of Silicon Valley Bank as a lender.
- Monitor subsequent filings for updates on the status of the Credit Facility and any changes in the company's liquidity position.
- Check the "Risk Factors" section of the 2022 10-K for a comprehensive list of risks beyond the banking situation.